Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 12
Submit an article Journal homepage
166
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy

Meng-Lan WangCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; View further author information
,
En-Qiang ChenCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; Correspondence[email protected]
View further author information
,
Chuan-Min TaoDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of ChinaView further author information
,
Tao-You ZhouCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; View further author information
,
Juan LiaoCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; View further author information
,
Dong-Mei ZhangCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; View further author information
,
Juan WangCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; View further author information
&
Hong TangCenter of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China; Correspondence[email protected]
View further author information
 show all
Pages 1420-1426 | Received 16 Jul 2017, Accepted 28 Aug 2017, Published online: 07 Sep 2017

References

  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.
  • Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.
  • Zoulim F, Lebosse F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol. 2016;18:109–116.
  • Cornberg M, Wong VW, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398–411.
  • Yu Y, Hou J, Omata M, et al. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int. 2014;8:39–54.
  • Kim JH, Choi YJ, Moon HW, et al. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. Clin Mol Hepatol. 2013;19:409–416.
  • Sali S, Sharafi H, Alavian SH, et al. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? Diagn Microbiol Infect Dis. 2015;82:114–119.
  • Zhu X, Gong Q, Yu D, et al. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. J Clin Virol. 2013;57:318–322.
  • Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449–454.
  • Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676–683.
  • Zoulim F, Carosi G, Greenbloom S, et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015;62:56–63.
  • Boglione L, Cardellino CS, De Nicolo A, et al. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. J Med Virol. 2014;86:1845–1850.
  • Gong DY, Chen EQ, Huang FJ, et al. Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. Viruses. 2013;5:1261–1271.
  • Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611–1620.
  • Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129.
  • Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275–281.
  • Chen EQ, Tang H. Optimization therapy for the treatment of chronic hepatitis B. World J Gastroenterol. 2014;20:5730–5736.
  • Chen EQ, Tang H. The current status of combination therapy of chronic hepatitis B. Eur Rev Med Pharmacol Sci. 2013;17:2023–2031.
  • Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923–931.
  • Peng CY, Lai HC, Su WP, et al. Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. Sci Rep. 2017;7:42879.
  • Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173.
  • Striki A, Manolakopoulos S, Deutsch M, et al. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 2017. [Epub ahead of print]. doi: 10.1111/liv.13432

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.